Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases

Pharmacy World and Science

Volumn 31, Issue 3, 2009, Pages 387-393

  Amir, Omalhassan ^a   Hassan, Yahaya ^a   Sarriff, Azmi ^a   Awaisu, Ahmed ^a   Abd Aziz, Noorizan ^a   Ismail, Omar ^b  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b HOSPITAL PULAU PINANG   (Malaysia)

Author keywords

ACE inhibitors; Drug drug interactions; Hyperkalemia; Incidence; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; CHLOROTHIAZIDE; ENALAPRIL; PERINDOPRIL; POTASSIUM CHLORIDE; RAMIPRIL; SPIRONOLACTONE;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG INFORMATION; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MORBIDITY; POLYPHARMACY; RATING SCALE; RISK ASSESSMENT; TERTIARY HEALTH CARE;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYPHARMACY; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 67349133204     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-009-9288-x     Document Type: Article

References (41)

1. DA Sica 2004 Angiotensin-converting enzyme inhibitors side effects: physiologic and non-physiologic considerations J Clin Hypertens 6 7 410 6 10.1111/j.1524-6175.2004.02866.x
2. MA Perazella RL Mahnensmith 1997 Hyperkalemia in the elderly drugs exacerbate impaired potassium homeostasis J Gen Intern Med 12 10 646 56 10.1046/j.1525-1497.1997.07128.x
3. GL Bakris MR Weir 2000 Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160 5 685 93 10.1001/archinte.160.5.685
4. CS Cruz AA Cruz CA Marcilio de Souza 2003 Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone Nephrol Dial Transplant 18 9 1814 9 10.1093/ndt/gfg295
5. RALES Investigators 1996 Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study, RALES) Am J Cardiol 78 6 902 7
6. C Anton AR Cox RDS Watson RE Ferner 2003 The safety of spironolactone treatment in patients with heart failure J Clin Pharm Ther 28 4 285 7 10.1046/j.1365-2710.2003.00491.x
7. B Palmer 2004 Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 6 585 92 10.1056/NEJMra035279
8. M Saito M Takada K Hirooka F Isobe Y Yasumura 2005 Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil J Clin Pharm Ther 30 6 603 10 10.1111/j.1365-2710.2005.00694.x
9. DN Juurlink MM Mamdani DS Lee A Kopp PC Austin A Laupacis DA Redelmeier 2004 Rates of hyperkalemia after publication of the randomized aldactone evaluation study N Engl J Med 351 6 543 51 10.1056/NEJMoa040135
10. E Wrenger R Muller M Moesenthin T Welte JC Frolich KH Neumann 2003 Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases BMJ 327 7407 147 9 10.1136/bmj.327.7407.147
11. M Svensson F Gustafsson S Galatius PR Hildebrandt D Atar 2004 How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10 4 297 303 10.1016/j.cardfail.2003.10.012
12. FH Ramadan N Masoodi AA El-Solh 2005 Clinical factors associated with hyperkalemia in patients with congestive heart failure J Clin Pharm Ther 30 7 233 9 10.1111/j.1365-2710.2005.00638.x
13. Chan LN, Horn JR. Management of metabolic drug interactions. In: Carter BL, Lake KD, Raebel MA, Bertch KE, Israel MK, Jermain DM, et al., editors. Pharmacotherapy Self-Assessment Program (PSAP). 3rd ed. Module 8. USA: ACCP; 2000. p. 102.
14. Hansten PD, Horn JR. Managing clinically important drug interactions. USA: Wolter Kluwer Health, Inc; 2005.
15. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook international. 14th ed. Hudson, Ohlo: Lexi-Comp Inc; 2006.
16. British National Formulary (BNF). Britain, R. P. S. O. G. 54th ed. London: BMJ Publishing Group Ltd and RPS Publishing; 2007.
17. Field A. Discovering statistics using SPSS. London: SAGE Publications Ltd; 2005. p. 208.
18. DW Hosmer S Taber S Lemeshow 1991 The importance of assessing the fit of logistic regression models: a case study Am J Public Health 81 12 1630 5
19. CI Obialo EO Ofili T Mirza 2002 Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease Am J Cardiol 90 663 5 10.1016/S0002-9149(02)02581-X
20. KP Tamirisa KD Aaronson TM Koelling 2004 Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure Am Heart J 148 971 8 10.1016/j.ahj.2004.10.005
21. LC Reardon DS Macpherson 1998 Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 158 26 32 10.1001/archinte.158.1.26
22. KB Shah K Rao R Sawyer SS Gottlieb 2005 The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure J Am Coll Cardiol 46 845 9 10.1016/j.jacc.2005.06.010
23. H Schepkens R Vanholder J Billiouw N Lameire 2001 Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases Am J Med 110 6 438 41 10.1016/S0002-9343(01)00642-8
24. B Pitt F Zannad WJ Remme R Cody A Castaigne A Perez 1999 The Effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES) N Engl J Med 341 709 17 10.1056/NEJM199909023411001
25. MA Raebel DL McClure KA Chan 2007 Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother 41 2 193 200 10.1345/aph.1H520
26. M Stevens R Dunlay 2000 Hyperkalemia in hospitalized patients Int Urol Nephrol 32 2 177 80 10.1023/A:1007135517950
27. S De Denus J Tardif M White MG Bourassa N Racine S Levesque A Ducharme 2006 Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials Am Heart J 152 4 705 12 10.1016/j.ahj.2006.05.030
28. Horn H. Hyperkalemia due to drug interactions. Pharm Times. 2004; www.hanstenandhorn.com . Accessed 28 Aug 2008.
29. AA Mangoni SHD Jackson 2003 Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol 57 1 6 14 10.1046/j.1365-2125.2003.02007.x
30. DW Bates EB Miller DJ Cullen L Burdick L Williams N Laird 1999 Patient risk factors for adverse drug events in hospitalized patients Arch Intern Med 159 21 2553 60 10.1001/archinte.159.21.2553
31. G Bente EA Stig D Kim 2005 Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant Eur J Clin Pharmacol 61 9 675 81 10.1007/s00228-005-0978-6
32. L Ramsay GT Tucker 1981 Drugs and the elderly BMJ 282 125 7
33. JV Butler H McAvoy D McEnroy EC Mulkerrin 2002 Spironolactone therapy in older patients-the impact of renal dysfunction Arch Gerontol Geriatr 35 1 45 9 10.1016/S0167-4943(01)00214-X
34. E Hay H Derazon N Bukish L Katz I Kruglyakov M Armoni 2002 Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet J Emerg Med 22 349 52 10.1016/S0736-4679(02)00434-1
35. SG Wannamethee AF Lever AG Shaper PH Whincup 1997 Serum potassium, cigarette smoking, and mortality in middle-aged Men Am J Epidemiol 145 7 598 606
36. SR Orth 2002 Smoking and the kidney J Am Soc Nephrol 13 6 1663 72 10.1097/01.ASN.0000018401.82863.FD
37. B Paice JM Gray D McBride T Donnelly DH Lawson 1983 Hyperkalaemia in patients in hospital BMJ 286 6372 1189 92
38. Y Hu JP Carpenter AT Cheung 2002 Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency Anesth Analg 95 1 39 41 10.1097/00000539-200207000-00006
39. D Weiner C Wingo 1998 Hyperkalemia: a potential silent killer J Am Soc Nephrol 9 1535 43
40. JH Gurwitz TS Field J Judge P Rochon LR Harrold C Cadoret 2005 The incidence of adverse drug events in two large academic long-term care facilities Am J Med 118 3 251 8 10.1016/j.amjmed.2004.09.018
41. D Heininger-Rothbucher S Bischinger H Ulmer C Pechlaner G Speer CJ Wiedermann 2001 Incidence and risk of potential adverse drug interactions in the emergency room Resuscitation 49 3 283 8 10.1016/S0300-9572(00)00363-4